Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Unusual surge in children’s pneumonia cases in England linked to Mycoplasma pneumoniae

Study reveals a significant and prolonged rise in pneumonia-related emergency visits among children in England, driven primarily by Mycoplasma pneumoniae infections during the winter of

August 15, 2024

Adjustment of growth guidance for 2024 and 2025 – Biotech Investments

Gerresheimer AG / Key word(s): Change in Forecast/Development of Sales Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025 30-Sep-2024 / 16:21 CET/CEST Disclosure

October 1, 2024

Selkirk Pharma announces new APS qualified facility with advanced fill/finish capacity in Spokane, WA

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced

February 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.